Why the study?
Upfront combination therapy including PGI2-IV is recognized as most appropriate for severe PAH, but reasons for non-use and comparative prognoses remain to be determined.
Does upfront combination therapy including intravenous prostaglandin I2 improve time to clinical worsening in adults with severe PAH compared to oral combination therapy alone?
Does upfront combination therapy including intravenous prostaglandin I2 improve time to clinical worsening in adults with severe PAH compared to oral combination therapy alone?
Answers are grounded in this paper and cite their sources.
In a real-world Japanese registry, upfront combination therapy including intravenous prostaglandin I2 for severe PAH was associated with improved hemodynamics and zero deaths or lung transplants, though statistical comparison was limited by small sample size.
Upfront combination therapy including intravenous prostaglandin I2 (PGI2-IV) is recognized as the most appropriate treatment for patients with severe pulmonary arterial hypertension (PAH). This retrospective study aimed to determine reasons why this therapy is not used for some patients with severe PAH and describe the hemodynamic and clinical prognoses of patients receiving initial combination treatment with (PGI2-IV+) or without (PGI2-IV−) PGI2-IV.
No takes yet. Share an insight, caveat, or question.
Tamura et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: